Please use this identifier to cite or link to this item:
|Title: ||Glycine transporter-1 inhibitor, N-methyglycine (sarcosine), added to clozapine for the treatment of schizophrenia|
|Authors: ||Lane, Hsien-yuan;Huang, Chieh-liang;Wu, Po-lun;Liu, Yi-ching;張玉坤;Chang, Yue-cune;張玉坤;Lin, Pao-yen;Chen, Po-wei;Tsai, Guochuan|
|Issue Date: ||2010-01-28|
Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics. Previous studies, however, found no advantage of D-serine, glycine, or D-cycloserine added to clozapine. The present study aims to determine the effects of sarcosine adjuvant therapy for schizophrenic patients receiving clozapine treatment.
Twenty schizophrenic inpatients enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/day) which was added to their stable doses of clozapine. Measures of clinical efficacy and side-effects were determined every other week.
Sarcosine produced no greater improvement when co-administered with clozapine than placebo plus clozapine at weeks 2, 4, and 6. Sarcosine was well tolerated and no significant side-effect was noted.
Unlike patients treated with other antipsychotics, patients who received clozapine treatment exhibit no improvement by adding sarcosine or agonists at the NMDA-glycine site. Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine’s unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents.
|Relation: ||Biological Psychiatry 60(6), pp.645-649|
|Appears in Collections:||[Graduate Institute & Department of Mathematics] Journal Article|
All items in 機構典藏 are protected by copyright, with all rights reserved.